Flu Shot Only Ten Per Cent Effective by Jeffrey Dach MD
The Australian Department of Health reported the Flu Vaccine is only 10% effective against the predominant strain of Influenza A (H3N2). (1-2) This doesn’t exactly inspire confidence in our Flu vaccine, which is the same one as Australia’s. The latest CDC study March 2022 by Dr Chung shows the flu vaccine is only 16% effective in the US.(30)
Twenty Two Thousand Nurses Refused Flu Shot
Twenty Two thousand nurses refused mandatory flu vaccination as precondition for hospital employment.(6) The nurses union at Harvard’s Women and Brigham’s hospital is suing the hospital to overturn mandatory Flu Shots for nurses.(5) December 2017, Nurses union lose their case and are forced to comply with mandatory flu shots or risk being fired.
David Brownstein says: FUGETABOUTIT !!
As Dr David Brownstein has said many times, “why would anyone want a Flu Shot that fails most people who get them?”(3-4)
Why Influenza Vaccines Fail (7-8)
Influenza A is an RNA virus present in birds and pigs, which mutates and changes rapidly.(7-8) The situation is made worse by overcrowding of animals by “modern industrial farming practices also called “Factory farming”. “The stress and unsanitary conditions…weaken animals’ immune systems, making them more susceptible to infection.“(Quote from The Week) The influenza virus may breed and mutate in animals, and then transmitted back to humans.(reference the CDC)
Dr Stephen Harrod Buhner has a nice description of what happens in his book: Herbal Antivirals:Natural Remedies for Emerging Resistant and Epidemic Viral Infections by Stephen Harrod Buhner.
“While DNA viruses make billions more of themselves, RNA viruses make billions of similar but not identical viruses. It is something like a swarm of honeybees — all similar but all different. In fact it is much more accurate to think of an RNA infection as infection by a viral swarm.”
The virus is a not a static genome. Rather, it is a rapidly mutating genome. As you can well imagine, it is virtually impossible to come up with an effective vaccine against such a moving target. This is especially true if last years viral strain is used as a template for a new vaccine. The virus has already changed.
High Dose Intravenous Vitamin C Treats Influenza and Prevents Pneumonis
There has been increased interest in the use of I.V. vitamin C since publication of curative results in the ICU setting for septic shock patients by Dr Paul Marik in Chest 2016. (11) Animal studies show that Vitamin C is essential for immune defense against influenza.(12-13) Dr. Hemilä in Nutrients 2017 reported vitamin C deficiency is associated with pneumonia. She identified 148 animal studies showing that vitamin C may alleviate or prevent infections caused by bacteria, viruses, and protozoa.(14)
Safety of High Dose IV Vitamin C
Safety of IV vitamin C has been evaluated in Phase One Clinical trials in three patients with B cell lymphoma (75 grams IV ) with serum ascorbate level of greater than 15 with no adverse events.(16). A second Clinical Trial in lung cancer patients with IV vitamin C (1.5 g/kg), three times a week for 4 weeks, likewise showed no adverse effects. Ascorbate serum levels were recorded in the range of 15-20 mMoles/L.(17) Both trials showed excellent safety profile with no adverse effects.
Combine Vitamin C, Vitamin D and Zinc for preventing Influenza
Dr Maggini in Vitamins Minerals 2017 says there’s a good scientific rationale for combining vitamin C, vitamin D and zinc to boost immune function in prevention of Influenza and other viral infections.(15)
Vitamin D for Prevention of Upper Respiratory Infections
Numerous studies have shown benefits with vitamin D3 supplementation for prevention of viral upper respiratory infection and pneumonia.(23,24) In BMJ 2017, Dr Adrian Martineau reviewed the literature on Vitamin D3 supplementation for prevention of acute respiratory infection. She concluded:
“Our study reports a major new indication for vitamin D supplementation: the prevention of acute respiratory tract infection.” (23)
Silver Nanoparticles Effective Against Influenza Virus
A number of in-vitro and in vivo studies have shown Silver Nanoparticles to be effective at prevention and treatment of viral, bacterial and fungal pathogens. (18-21). A number of studies showed efficacy against influenza virus strains. A 2009 study found that “Nanosilver has destructive effect on the virus membrane glycoprotein knobs as well as the cells.”(21) Silver Nanoparticle products are widely available as over-the-counter health remedies, no prescription needed.
Flu Shot and Cancer
A study by Dr Lankes at the Feinberg School of Medicine of Northwestern University found that the flu shot increases the risk of non-Hodgkin lymphoma by 53%, follicular lymphoma by 98% percent, and diffuse large B cell lymphoma by 88%. (9)
Flu Shot Contains 25 mcg of Mercury Which Exceeds EPA Maximum
Exposure to Mercury, a known neurotoxin, is associated with ADD, ADHD in children, as well as other adverse neuro-developmental effects. (31-33)
Government Reimbursement/ Financial Incentives and Penalties tied to Vaccination Rates
Nurses Against Mandatory Vaccination have reported that,”hospital employee vaccination rates are tied to government reimbursement rates.” In other words, hospital policy requiring mandatory flu shot is tied to government reimbursement rates. These rules are written for the financial benefit of the drug industry by “revolving door” government officials, who have been, or will be employees of the drug industry. The details are elaborated in this article on Mercola.com.
Financial Incentives for Pediatricians for High Vaccination Rates
A pediatrician is paid $40,000 bonus-incentive by Blue Cross Blue Shield for each 100 patients under the age of 2 who are fully vaccinated. For 200 patients, this annual bonus increases to $80,000. That is a hefty financial incentive which is difficult to resist. This information is found in Blue Cross Blue Shield 2016 PROVIDER INCENTIVE PROGRAM Childhood immunizations combo 10
Above Chart: which includes FLU SHOT, from Blue Cross Blue Shield Document outlining financial incentives for pediatricians per fully vaccinated child under two years of age.
Update Sept 2022
2017 study published in NEJM by Dr Jakson: Live Attenuated Flu Vaccine had no effectiveness for children 2-17, and not recommended for use in United States. (28-29)
Key findings of the study were that overall effectiveness of all vaccines was 48% (95% confidence interval 41-55), but LAIV had no effectiveness (5%; 95% CI -47 to 39) for children 2 – 17 years of age. That’s why, together with other studies showing similar results, LAIV is not recommended for use in the United States.. (29) Endquote Dr Jackson.
2021-2022 Flu Season Efficacy of Flu Vaccine only 16% According to CDC study March 2022 by Jessie R. Chung, MD . (30)
Based on data from 3,636 children, adolescents, and adults with acute respiratory infection during October 4, 2021–February 12, 2022, seasonal influenza vaccination did not reduce the risk for outpatient respiratory illness caused by influenza A(H3N2) viruses that have predominated so far this season. Endquote Dr Chung (30)
Update October 2022: Robert Malone MD explains the logic behind annual flu shots speaking at Florida Health Summit
Conclusion: Any one for an annual flu shot?
Above header image Flu shot sign in front of Walgreens courtesy of Coronado Times.
Articles with related reference:
Antiviral Herbals Stephen Buhner
Vitamin C saves Man Dying of Pneumonia
Intravenous Vitamin C as Cancer Chemotherapy
Jeffrey Dach MD
7450 Griffin Road Suite 190
Davie Florida 33314
Links and References:
1) Perspective Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine Catharine I. Paules, M.D., Sheena G. Sullivan, M.P.H., Ph.D., Kanta Subbarao, M.B., B.S., M.P.H., and Anthony S. Fauci, M.D. November 29, 2017DOI: 10.1056/NEJMp1714916
according to the Australian Government Department of Health. Influenza A (H3N2) viruses predominated, and the preliminary estimate of vaccine effectiveness against influenza A (H3N2) was only 10%.
2) Australia’s flu season has U.S. health officials bracing for a bad winter — and wishing for a new vaccine. LA Times
The most common flu strain there was the influenza A virus known as H3N2, and the vaccine given to Australians had an effectiveness of only 10%, according to preliminary estimates.
The vaccine now being administered to Americans uses the same formulation. Even worse, nearly three-quarters of the 1,544 laboratory-confirmed cases of flu seen in the U.S. since Oct. 1 were of the H3N2 variety, according to the Centers for Disease Control and Prevention.
3) Time For A Flu Vaccine? Fugetaboutit! By Dr. David Brownstein
Dr. Brownstein’s Holistic Medicine September 25, 2017
4) Dr. Brownstein: Flu Vaccines Fail Nearly all Who Get Them
Flu vaccines fail nearly all who get them. It is a ludicrous argument to mandate flu vaccines for health care workers and others. The Big Pharma Cartel wants all 350 million of us to get vaccinated yearly in order to prevent the flu. That might be reasonable if the flu vaccine is beneficial to most who receive it. It is not.
5) Brigham and Women’s mandatory flu shot policy prompts nursing suit: 7 things to know Written by Kelly Gooch | September 27, 2017 |
A union representing nurses at Boston-based Brigham and Women’s Hospital is standing up against the facility’s new policy mandating flu vaccines for employees, reports The Boston Globe.
6) 22,000 Nurses Refuse *Mandatory* Vaccinations Fighting for the right to choose Christina Sarich by Christina Sarich January 9, 2016
7) Why flu vaccines so often fail By Jon CohenSep. 20, 2017 , 2:30 PM
8) Resa-Infante, Patricia, et al. “The influenza virus RNA synthesis machine: advances in its structure and function.” RNA biology 8.2 (2011): 207-215.
9) Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC. Vaccination history and risk of non-hodgkin lymphoma: a population-based, case-control study. Cancer Causes Control. 2009 Jul;20(5):517-23. Epub 2008 Nov 15.
10) American Thoracic Society (2009, May 20). Children Who Get Flu Vaccine Have Three Times Risk Of Hospitalization For Flu, Study Suggests. ScienceDaily. Retrieved May 20, 2009
Ascorbate antiviral effects
11) IV Vitamin C Curative for Septic Shock by Paul Marik in Chest 2016:
Marik, Paul E., et al. “Hydrocortisone, Vitamin C and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.” CHEST Journal (2016). Hydrocortisone Vitamin C and Thiamine for Sepsis Marik Paul E CHEST 2016
The global burden of sepsis is estimated as 15 to 19 million cases annually, with a mortality rate approaching 60% in low-income countries.
Methods In this retrospective before-after clinical study, we compared the outcome and clinical course of consecutive septic patients treated with intravenous vitamin C, hydrocortisone, and thiamine during a 7-month period (treatment group) with a control group treated in our ICU during the preceding 7 months. The primary outcome was hospital survival. A propensity score was generated to adjust the primary outcome.
Results There were 47 patients in both treatment and control groups, with no significant differences in baseline characteristics between the two groups. The hospital mortality was 8.5% (4 of 47) in the treatment group compared with 40.4% (19 of 47) in the control group (P < .001). The propensity adjusted odds of mortality in the patients treated with the vitamin C protocol was 0.13 (95% CI, 0.04-0.48; P = .002). The Sepsis-Related Organ Failure Assessment score decreased in all patients in the treatment group, with none developing progressive organ failure. All patients in the treatment group were weaned off vasopressors, a mean of 18.3 ± 9.8 h after starting treatment with the vitamin C protocol. The mean duration of vasopressor use was 54.9 ± 28.4 h in the control group (P < .001).
Conclusions Our results suggest that the early use of intravenous vitamin C, together with corticosteroids and thiamine, are effective in preventing progressive organ dysfunction, including acute kidney injury, and in reducing the mortality of patients with severe sepsis and septic shock. Additional studies are required to confirm these preliminary findings.
12) Kim, Yejin, et al. “Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-α/β at the initial stage of influenza A virus (H3N2) infection.” Immune network 13.2 (2013): 70-74.
L-ascorbic acid (vitamin C) is one of the well-known anti-viral agents, especially to influenza virus. Since the in vivo anti-viral effect is still controversial, we investigated whether vitamin C could regulate influenza virus infection in vivo by using Gulo (-/-) mice, which cannot synthesize vitamin C like humans. First, we found that vitamin C-insufficient Gulo (-/-) mice expired within 1 week after intranasal inoculation of influenza virus (H3N2/Hongkong). Viral titers in the lung of vitamin C-insufficient Gulo (-/-) mice were definitely increased but production of anti-viral cytokine, interferon (IFN)-α/β, was decreased. On the contrary, the infiltration of inflammatory cells into the lung and production of pro-inflammatory cytokines, tumor necrosis factor (TNF)-α and interleukin (IL)-α/β, were increased in the lung. Taken together, vitamin C shows in vivo anti-viral immune responses at the early time of infection, especially against influenza virus, through increased production of IFN-α/β.
13) Li, Wei, Nobuyo Maeda, and Melinda A. Beck. “Vitamin C deficiency increases the lung pathology of influenza Virus–Infected gulo−/− mice.” The Journal of nutrition 136.10 (2006): 2611-2616.
This study was designed to determine the effects of vitamin C deficiency on the immune response to infection with influenza virus. l-Gulono-gamma-lactone oxidase gene-inactivated mice (gulo-/- mice) require vitamin C supplementation for survival. Five-wk-old male and female gulo-/- mice were provided water or water containing 1.67 mmol/L vitamin C for 3 wk before inoculation with influenza A/Bangkok/1/79. There were no differences in lung influenza virus titers between vitamin C-adequate and -deficient mice; however, lung pathology in the vitamin C-deficient mice was greater at 1 and 3 d after infection but less at d 7 compared with vitamin C-adequate mice. Male vitamin C-deficient mice had higher expression of mRNA for regulated upon activation normal T expressed and secreted (RANTES), IL-1beta, and TNF-alpha in the lungs at d 1 after infection compared with male controls. However, at d 3 after infection, male vitamin C-deficient mice had less expression of mRNA for RANTES, monocyte chemotactic protein-1 (MCP-1), and IL-12 compared with male controls. None of these differences were observed in female mice. Vitamin C-deficient male mice also had greater nuclear factor-kappaB activation as early as 1 d after infection compared with male controls. These data suggest that vitamin C is required for an adequate immune response in limiting lung pathology after influenza virus infection.
14) Hemilä, Harri. “Vitamin C and Infections.” Nutrients 9.4 (2017): 339.
In the early literature, vitamin C deficiency was associated with pneumonia. After its identification, a number of studies investigated the effects of vitamin C on diverse infections. A total of 148 animal studies indicated that vitamin C may alleviate or prevent infections caused by bacteria, viruses, and protozoa. The most extensively studied human infection is the common cold. Vitamin C administration does not decrease the average incidence of colds in the general population, yet it halved the number of colds in physically active people. Regularly administered vitamin C has shortened the duration of colds, indicating a biological effect. However, the role of vitamin C in common cold treatment is unclear. Two controlled trials found a statistically significant dose–response, for the duration of common cold symptoms, with up to 6–8 g/day of vitamin C. Thus, the negative findings of some therapeutic common cold studies might be explained by the low doses of 3–4 g/day of vitamin C. Three controlled trials found that vitamin C prevented pneumonia. Two controlled trials found a treatment benefit of vitamin C for pneumonia patients. One controlled trial reported treatment benefits for tetanus patients. The effects of vitamin C against infections should be investigated further.
15) Maggini, S., et al. “Vitamins C, D and Zinc: Synergistic Roles in Immune Function and Infections.” Vitam Miner 6.167 (2017): 2376-1318. Vitamins C D Zinc Synergistic Immune Function Infections Maggini Vitam Miner 2017
The evidence presented here indicates that there’s a good scientific rationale for combining vitamin C, vitamin D and zinc in order to support and modulate immune functions
IV Vitamin C for Relapsed Refractory B cell lymphoma
KAWADA, Hiroshi, et al. “Phase I Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin’s Lymphoma.” The Tokai journal of experimental and clinical medicine 39.3 (2014): 111-115.
PURPOSE:To determine the safety and the appropriate dose of intravenous l-ascorbic acid (AA) in conjunction with chemotherapy for patients with relapsed lymphoma.
PATIENTS AND METHODS:Patients with relapsed CD20-positive B-cell non-Hodgkin’s lymphoma, who were going to receive the CHASER regimen as salvage therapy, were enrolled and treated with escalating doses of AA administered by drip infusion after the 2nd course of the CHASER regimen. The target plasma concentration immediately after AA administration was >15 mM (264 mg/dl).
RESULTS: A serum AA concentration of >15 mM was achieved in 3 sequentially registered patients, all of whom had received a 75 g whole body dose. No obvious adverse drug reaction was observed in the patients. The trial was therefore successfully completed.
CONCLUSION:Intravenous AA at a whole body dose of 75 g appears to be safe and sufficient to achieve an effective serum concentration. A phase II trial to evaluate the efficacy of intravenous AA in relapsed/refractory lymphoma patients will now be initiated.
17) Ou, Junwen, et al. “The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer.” European Journal of Pharmaceutical Sciences 109 (2017): 412-418.
Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. However, there are no safety and pharmacokinetics data in Chinese cancer patients. We carried out a clinical trial to evaluate the safety and pharmacokinetics of those methods in patients with stage III-IV non-small cell lung cancer (NSCLC). Blood ascorbic acid in the fasting state was obtained from 35 NSCLC patients; selecting from them 15 patients with stage III-IV entered the phase I study. They were randomized allocated into 3 groups, and received doses 1.0, 1.2, 1.5 g/kg AA infusions. Participants in the first group received intravenous AA (IVAA) when mEHT was finished, in the second group IVAA was administered simultaneously with mEHT and in the third group IVAA was applied first, and followed with mEHT. Pharmacokinetic profiles were obtained when they received solely IVAA and when IVAA in combination with mEHT. The process was applied 3 times a week (every other day, weekend days off) for 4 weeks. We found that fasting plasma AA levels were significantly correlated with stage of the disease. Peak concentration of AA was significantly higher in the simultaneous treatments than in other combinations with mEHT or in solely IVAA-managed groups. IVAA synergy with simultaneous mEHT is safe and the concomitant application significantly increases the plasma AA level for NSCLC patients.
18) Xiang, Dong-xi, et al. “Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro.” Journal of virological methods 178.1-2 (2011): 137-142.
19) Xiang, Dongxi, et al. “Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo.” International journal of nanomedicine 8 (2013): 4103.
Silver nanoparticles (AgNPs) have attracted much attention as antimicrobial agents and have demonstrated efficient inhibitory activity against various viruses, including human immunodeficiency virus, hepatitis B virus, and Tacaribe virus. In this study, we investigated if AgNPs could have antiviral and preventive effects in A/Human/Hubei/3/2005 (H3N2) influenza virus infection. Madin-Darby canine kidney cells infected with AgNP-treated H3N2 influenza virus showed better viability (P<0.05 versus influenza virus control) and no obvious cytopathic effects compared with an influenza virus control group and a group treated with the solvent used for preparation of the AgNPs. Hemagglutination assay indicated that AgNPs could significantly inhibit growth of the influenza virus in Madin-Darby canine kidney cells (P<0.01 versus the influenza virus control). AgNPs significantly reduced cell apoptosis induced by H3N2 influenza virus at three different treatment pathways (P<0.05 versus influenza virus control). H3N2 influenza viruses treated with AgNPs were analyzed by transmission electron microscopy and found to interact with each other, resulting in destruction of morphologic viral structures in a time-dependent manner in a time range of 30 minutes to 2 hours. In addition, intranasal AgNP administration in mice significantly enhanced survival after infection with the H3N2 influenza virus. Mice treated with AgNPs showed lower lung viral titer levels and minor pathologic lesions in lung tissue, and had a marked survival benefit during secondary intranasal passage in vivo. These results provide evidence that AgNPs have beneficial effects in preventing H3N2 influenza virus infection both in vitro and in vivo, and demonstrate that AgNPs can be used as potential therapeutics for inhibiting outbreaks of influenza.
20) Lara, Humberto H., et al. “Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds.” Journal of nanobiotechnology 9.1 (2011): 30.
21) ANTIVIRAL EFFECT OF NANOSILVER ON INFLUENZA VIRUS MEHRBOD DARU J PHARM SCI 2009 DARU JOURNAL OF PHARMACEUTICAL SCIENCE SPRING 2009 , Volume 17 , Number 2; Page(s) 88 To 93. Author(s): MEHRBOD P., MOTAMED N., TABATABAEIAN M., SOLEYMANI ESTIAR R., AMINI E., SHAHIDI M., KHEYRI M.T.*
Introduction: Influenza is a viral infectious disease with frequent seasonal epidemics causing world-wide economical and social effects. Due to antigenic shifts and drifts of influenza virus, long-lasting vaccine has not been developed so far. The current annual vaccines and effective antiviral drugs are not available sufficiently. Therefore in order to prevent spread of infectious agents including viruses, antiseptics are considered by world health authorities. Small particles of silver have a long history as general antiseptic and disinfectant. Silver does not induce resistance in microorganisms and this ability in Nanosize is stronger.
Materials and methods: The aim of this study was to determine antiviral effects of Nanosilver against influenza virus. TCID50 (50% Tissue Culture Infectious Dose) of the virus as well as CC50 (50% Cytotoxic Concentration) of Nanosilver was obtained by MTT (3- [4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide, Sigma) method. This compound was non-toxic to MDCK (Madin-Darbey Canin Kidney) cells at concentration up to 1 mg/ml. Effective minimal cytotoxic concentration and 100 TCID50 of the virus were added to the confluent cells. Inhibitory effects of Nanosilver on the virus and its cytotoxicity were assessed at different temperatures using Hemagglutination (HA) assay, RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction), and DIF (Direct Immunofluorescent). RT-PCR and free band densitometry software were used to comparethe volume of the PCR product bands on the gel.
Results and Discussion: In this study it was found that Nanosilver has destructive effect on the virus membrane glycoprotein knobs as well as the cells.
22) Bought the Movie
Vitamin D anti influenza
23) Martineau, Adrian R., et al. “Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.” bmj 356 (2017): i6583.
Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect.
Design Systematic review and meta-analysis of individual participant data (IPD) from randomised controlled trials.
Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and the International Standard Randomised Controlled Trials Number registry from inception to December 2015.
Eligibility criteria for study selection Randomised, double blind, placebo controlled trials of supplementation with vitamin D3 or vitamin D2 of any duration were eligible for inclusion if they had been approved by a research ethics committee and if data on incidence of acute respiratory tract infection were collected prospectively and prespecified as an efficacy outcome.
Results 25 eligible randomised controlled trials (total 11 321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10 933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio 0.88, 95% confidence interval 0.81 to 0.96; P for heterogeneity <0.001). In subgroup analysis, protective effects were seen in those receiving daily or weekly vitamin D without additional bolus doses (adjusted odds ratio 0.81, 0.72 to 0.91) but not in those receiving one or more bolus doses (adjusted odds ratio 0.97, 0.86 to 1.10; P for interaction=0.05). Among those receiving daily or weekly vitamin D, protective effects were stronger in those with baseline 25-hydroxyvitamin D levels <25 nmol/L (adjusted odds ratio 0.30, 0.17 to 0.53) than in those with baseline 25-hydroxyvitamin D levels ≥25 nmol/L (adjusted odds ratio 0.75, 0.60 to 0.95; P for interaction=0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (adjusted odds ratio 0.98, 0.80 to 1.20, P=0.83). The body of evidence contributing to these analyses was assessed as being of high quality.
Conclusions Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.
Conclusions and policy implications: Our study reports a major new indication for vitamin D supplementation: the prevention of acute respiratory tract infection. We also show that people who are very deficient in vitamin D and those receiving daily or weekly supplementation without additional bolus doses experienced particular benefit. Our results add to the body of evidence supporting the introduction of public health measures such as food fortification to improve vitamin D status, particularly in settings where profound vitamin D deficiency is common.
24) Guo, Lin-Ying, et al. “Relationship Between Vitamin D Status and Viral Pneumonia in Children.” Pediatric Allergy, Immunology, and Pulmonology 30.2 (2017): 86-91.
This study investigated the impact of vitamin D status on the susceptibility and severity of viral pneumonia (VP) in children. A total of 236 children with VP, aged from 1 month to 14 years, and 271 gender and age matched healthy children to compare the serum 25(OH)D levels and vitamin D status. Vitamin D indices were compared between subgroups in VP cases. The median [interquartile range (IQR)] serum 25(OH)D level in these 507 children was 23.7 (IQR 17.5–30.6) ng/mL; 134 (26.4%) children were vitamin D sufficient [25(OH)D ≥30 ng/mL], whereas 373 (73.6%) were insufficient, which included insufficient [25(OH)D 20–30 ng/mL], deficient [25(OH)D 10–20 ng/mL], and severely deficient [25(OH)D ≤10 ng/mL]. The median (IQR) serum 25(OH)D level in the VP group was significantly lower than that in the control group [19.6 (12.3–26.4) ng/mL versus 26.6 (21.4–32.9) ng/mL] (P < 0.001). The proportions of vitamin D deficiency (32.2% versus 19.5%) and severe deficiency (19.1% versus 0.4%) in the VP group were significantly higher than those in the control group (P < 0.001). As vitamin D status decreased, the odds ratio (95% confidence interval) for VP showed an increasing trend [sufficiency (0.3; 0.2–0.5), insufficiency (0.9; 0.6–1.3), deficiency (2.0; 1.3–2.9), and severe deficiency (51.7; 7.2–372.2)]. The median (IQR) serum 25(OH)D level in the VP subgroup who accepted mechanical ventilation was significantly lower than that in the nonmechanical ventilation subgroup [12.9(6.5–22.5) ng/mL versus 20.8 (14.2–28.0) ng/mL] (P < 0.001). Poor vitamin D status might be related to the susceptibility and severity of VP in children.
25) Biondi, Eric A., and C. Andrew Aligne. “Flu Vaccine for All: A Critical Look at the Evidence.” (2015). Biondi Flu Vaccine for All A Critical Look at the Evidence 2015
26) The-Flu-Vaccine-is-Bad-Medicine Meehan, Jim. Independent and unbiased science against the flu vaccine: why it is ineffective, unnecessary, and bad medicine.
●Why Tamiflu is really bad medicine
●Natural Solutions for Preventing Influenza
Nowhere is the scientific fraud and betrayal of public trust more manifest than in the promotion of untested and unsafe vaccines like the flu vaccine.
Cochrane meta-analysis of 90 plus research studies conclude that the flu vaccine is neither effective nor recommended.
At best, the flu vaccine has been less than 50% effective, most years less than 20% effective against influenza A and B, which represent about 10% of the circulating viruses responsible for causing cold and flu like symptoms.
27) Lenzer Jeanne Belief not science is behind flu jab promotion BMJ 2012.
LAIV had no effectiveness (5%; 95% CI -47 to 39) for children 2 – 17 years of age. That’s why, together with other studies showing similar results, LAIV is not recommended for use in the United States.
28) How Effective Are Influenza Vaccines? : Amer Academy of Pediatrics November 7, 2017 Most healthcare providers are aware of the lack of effectiveness of the live attenuated influenza vaccine (LAIV), apparent in recent flu seasons. Some also were surprised by what appeared to be a relatively low effectiveness rate for the other flu vaccines. I’ll try to explain all this here, using this recently published, important study.Bud Wiederman, MD, MA, Evidence eMended Editor, Grand Rounds
29) Jackson ML, Chung JR, Jackson LA, et al. Influenza vaccine effectiveness in the United States during the 2015-2016 season. N Engl J Med. 2017;377(6):534-543;
Key findings of the study were that overall effectiveness of all vaccines was 48% (95% confidence interval 41-55), but LAIV had no effectiveness (5%; 95% CI -47 to 39) for children 2 – 17 years of age. That’s why, together with other studies showing similar results, LAIV is not recommended for use in the United States.
Flu Vaccine Was Not Very Effective This Season, the C.D.C. Says
The vaccine was only about 16 percent effective at reducing a person’s chance of getting a mild or moderate infection, the
30) Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness — United States, February 2022
Weekly / March 11, 2022 / 71(10);365–370 Jessie R. Chung, MPH1;
Among participants with a positive influenza test result, 41% had received the 2021–22 seasonal influenza vaccine, compared with 50% of influenza test result–negative participants (Table 2). VE against outpatient medically attended ARI associated with influenza A virus types was 14% (95% CI = −17% to 37%). VE for all ages combined was 16% (95% CI = −16% to 39%) against outpatient medically attended ARI associated with influenza A(H3N2) virus infection.
Based on data from 3,636 children, adolescents, and adults with acute respiratory infection during October 4, 2021–February 12, 2022, seasonal influenza vaccination did not reduce the risk for outpatient respiratory illness caused by influenza A(H3N2) viruses that have predominated so far this season.
31) Mercury in Vaccines Exceed EPA’s Maximum by Dr. Hansen
1 microgram (mcg) of Mercury per 0.5mL vaccine dose is equivalent to 2000 mcg per liter, which equals 2000 parts per billion (2000 ppb).
2 ppb mercury is the U.S. EPA limit for drinking water (http://www.epa.gov/safewater/contaminants /index.html#mcls).
20 ppb mercury destroys neurite membranes (nerve tissue in the brain) (Leong et al., Neuroreport 2001; 12:733-7). An amount thought to be sufficient to cause Autism.
200 ppb mercury is the level in liquid that the EPA classifies as hazardous waste (http://www.epa.gov/ epaoswer/hazwaste/mercury/ regs.htm#hazwaste).
25,000 ppb mercury is equivalent to 25 mcg, which is the concentration of mercury in each dose dispensed from the multi-dose vials of both the seasonal influenza vaccine as well as the pandemic H1N1 flu vaccine in the U.S.
According to the EPA, the maximum acceptable daily risk level is 0.1 mcg/kg. The current vaccine will inject the average child with 12-17 times the maximum daily amount of mercury recommended by the EPA and the average adult with 3.5 times the maximum amount. However, most concerning is the fact that the vaccines will expose the unborn fetus of a pregnant women to 250 times the maximum recommended dose of mercury.
32) Sagiv SK, Thurston SW, Bellinger DV, Amarasiriwardena C, Korrick SA. Prenatal Exposure to Mercury and Fish Consumption During Pregnancy and Attention-Deficit/Hyperactivity Disorder–Related Behavior in Children. Arch Pediatr Adolesc Med. 2012;():1-9. doi:10.1001/archpediatrics.2012.1286.
33) Ke, Tao, et al. “Developmental exposure to methylmercury and ADHD, a literature review of epigenetic studies.” Environmental Epigenetics 7.1 (2021): dvab014.
34) The Video – “Bought” a 2015 movie by Jeff Hayes, Written and Directed by Bobby Sheehan. The story behind vaccines and big pharma.
Jeffrey Dach MD
7450 Griffin Road, Suite 190
Davie, Fl 33314
Disclaimer click here: www.drdach.com/wst_page20.html
The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician — patient relationship. Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.
Copyright (c) 2017-2022 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given.
FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.
Serving Areas of: Hollywood, Aventura, Miami, Fort Lauderdale, Pembroke Pines, Miramar, Davie, Coral Springs, Cooper City, Sunshine Ranches, Hallandale, Surfside, Miami Beach, Sunny Isles, Normandy Isles, Coral Gables, Hialeah, Golden Beach ,Kendall,sunrise, coral springs, parkland,pompano, boca raton, palm beach, weston, dania beach, tamarac, oakland park, boynton beach, delray,lake worth,wellington,plantation
Comments From Facebook
Rita Celone Umile: quite a risk for something that doesn’t always work
Juan Trujillo: Got the flu shot this year, and guest what? I got the flu, bummer!!
Larry Wilner : As a fellow doc, the thing that infuriates me the most about the Lancet
article is that instead of acknowledging the lack of data for the flu
shot in those of us over and 65 and recommending more studies, the
people who make the decisions just came out with a “new” flu shot with
twice the antigen and hoped it would work. Jeez.
Melissa Smith-Shepherd Health & Wellness:
Thanks Dr Jeffrey Dach for this great information! Merry Christmas!
Lisa Greene-Daggett :
The only time I ever got a flu shot I nearly died from the flu. I was told
it wasn’t the shot the made me sick. I just got a strain of the flu that
wasn’t the same a the one the shot protected me against. I call lies on